A National Danish Effectiveness Study of Ocrelizumab Versus Natalizumab in Multiple Sclerosis.

ABSTRACT:

Background

Ocrelizumab and natalizumab are highly effective disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS). Direct comparison of effectiveness is crucial for optimizing treatment decisions and improving patient outcomes. The aim was to compare any difference in effectiveness of ocrelizumab and natalizumab on disease activity and progression in RRMS.

Methods

This was a national multicenter comparative effectiveness research study using data from the nationwide population-based registry of MS cases in Denmark. Patients were included from January 2018 to April 2023 with a history of RRMS treated with ocrelizumab or natalizumab. Inverse probability of treatment weighting based on propensity scores was applied. Main outcomes were the comparison of

SUBMITTER: Maersk-Moller C 

PROVIDER: S-EPMC12848903 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature